Novavax doubles down on promise to produce 2B Nuvaxovid doses — this year
If there’s one thing Novavax executives wanted to push across in the company’s 2021 Q4 earnings call Monday, it’s that, after months of struggles, it is in a position to manufacture 2 billion doses of its Covid-19 vaccine.
CEO Stanley Erck, CMO Filip Dubovsky and chief business and commercial officer John Trizzino hammered that home to investors in the company’s call Monday. It’s a potential bright spot, finally, after manufacturing issues affecting the purity of the drugs had left a huge deficiency in the world’s supply of Covid-19 vaccines to lower- and middle-income countries through the COVAX program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
